Filter posts

The Challenges and Risks of Adopting Foreign Price Controls

The Trump Administration is moving forward with a plan to import foreign price controls into …

Oncologist Warns of IPI’s Potentially Dangerous Implications

Writing for Morning Consult, Dr. Lucy Langer, a clinical oncologist with Compass Oncology in Portland, …

Despite Administration’s “Sky-High Rhetoric,” Importing Foreign Price Controls Will Harm Innov...

In October of 2018, the Trump Administration outlined a proposal that would import foreign price …

The Administration’s Orwellian Defense of Importing Foreign Price Controls

The Trump administration is out with a new blog post defending its plan to adopt …

Think the Drug-Pricing debate addresses Patient Costs? Think again.

Writing for The Hill, BIO President and CEO Jim Greenwood tackled the drug pricing debate …

Patient Advocates Sounding the Alarm Over Fail First

The Centers for Medicare & Medicaid Services (CMS) has reversed a long-standing policy allowing Medicare …

Watchdog Report Reaffirms Concerns With Fail First

A new report by the Office of Inspector General at the U.S. Department of Health …

Hits to Patients Keep on Coming

At a time when prescription drug prices and spending are remarkably stable, patients are getting …

On the President’s Drug Cost Plan, Three Important Concerns

Part 2. Upending Access in Medicare Part B program This week, BIO launched a three-part …

Cancer Docs Weigh in on Medicare Part B Demo

This week, American Society of Clinical Oncology (ASCO) President Daniel Hayes, MD and CEO Clifford …